Xenetic Biosciences, Inc. (XBIO)
XBIO Stock Price Chart
Explore Xenetic Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze XBIO price movements and trends.
XBIO Company Profile
Discover essential business fundamentals and corporate details for Xenetic Biosciences, Inc. (XBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jun 2016
Employees
2.00
Website
https://www.xeneticbio.comCEO
James F. Parslow
Description
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
XBIO Financial Timeline
Browse a chronological timeline of Xenetic Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 Aug 2026
Earnings released on 12 May 2026
EPS came in at -$0.20 , while revenue for the quarter reached $806.92k .
Earnings released on 12 Mar 2026
EPS came in at -$0.22 surpassing the estimated -$0.52 by +57.69%, while revenue for the quarter reached $766.30k , beating expectations by +11.06%.
Earnings released on 12 Nov 2025
EPS came in at -$0.33 surpassing the estimated -$0.49 by +32.65%, while revenue for the quarter reached $1.03m , beating expectations by +63.01%.
Earnings released on 12 Aug 2025
EPS came in at -$0.45 surpassing the estimated -$0.64 by +29.69%, while revenue for the quarter reached $589.90k , beating expectations by +23.15%.
Earnings released on 12 May 2025
EPS came in at -$0.59 surpassing the estimated -$0.72 by +18.06%, while revenue for the quarter reached $590.00k , missing expectations by -11.94%.
Earnings released on 18 Mar 2025
EPS came in at -$0.68 matching the estimated -$0.68, while revenue for the quarter reached $650.00k , meeting expectations.
Earnings released on 12 Nov 2024
EPS came in at -$0.28 falling short of the estimated -$0.14 by -100.00%, while revenue for the quarter reached $614.24k , missing expectations by -18.10%.
Earnings released on 13 Aug 2024
EPS came in at -$0.83 matching the estimated -$0.83, while revenue for the quarter reached $726.40k , beating expectations by +34.52%.
Earnings released on 9 May 2024
EPS came in at -$0.78 surpassing the estimated -$0.79 by +1.27%, while revenue for the quarter reached $510.82k , missing expectations by -21.41%.
Earnings released on 21 Mar 2024
EPS came in at -$0.77 surpassing the estimated -$0.87 by +11.49%, while revenue for the quarter reached $671.96k , missing expectations by -1.18%.
Earnings released on 10 Nov 2023
EPS came in at -$0.69 surpassing the estimated -$1.12 by +38.39%, while revenue for the quarter reached $611.17k , missing expectations by -10.12%.
Earnings released on 11 Aug 2023
EPS came in at -$0.69 surpassing the estimated -$1.13 by +38.94%, while revenue for the quarter reached $651.01k , beating expectations by +47.96%.
Stock split effective on 15 May 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$0.60 surpassing the estimated -$1.10 by +45.45%, while revenue for the quarter reached $605.84k , beating expectations by +47.77%.
Earnings released on 23 Mar 2023
EPS came in at -$1.00 falling short of the estimated -$0.09 by -1.01k%, while revenue for the quarter reached $486.97k , missing expectations by -0.62%.
Earnings released on 10 Nov 2022
EPS came in at -$0.60 surpassing the estimated -$1.80 by +66.67%, while revenue for the quarter reached $414.25k , beating expectations by +1.04%.
Earnings released on 12 Aug 2022
EPS came in at -$1.90 falling short of the estimated -$1.20 by -58.33%, while revenue for the quarter reached $416.71k , missing expectations by -0.78%.
Earnings released on 12 May 2022
EPS came in at -$1.20 falling short of the estimated -$1.10 by -9.09%, while revenue for the quarter reached $388.99k , beating expectations by +94.50%.
Earnings released on 22 Mar 2022
EPS came in at -$1.80 falling short of the estimated -$1.50 by -20.13%, while revenue for the quarter reached $332.60k , beating expectations by +232.60%.
Earnings released on 12 Nov 2021
EPS came in at -$1.30 falling short of the estimated -$1.20 by -8.33%, while revenue for the quarter reached $349.27k , beating expectations by +9.09%.
Earnings released on 12 Aug 2021
EPS came in at -$1.30 surpassing the estimated -$1.60 by +18.75%, while revenue for the quarter reached $287.60k , beating expectations by +51.37%.
XBIO Stock Performance
Access detailed XBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
